Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 114 entries
Sorted by: Best Match Show Resources per page
Economic incentives in clinical investigation.

The New England journal of medicine

Relman AS.
PMID: 2927464
N Engl J Med. 1989 Apr 06;320(14):933-4. doi: 10.1056/NEJM198904063201410.

No abstract available.

Cite
Relman AS. Economic incentives in clinical investigation. N Engl J Med. 1989;320(14):933-4doi: 10.1056/NEJM198904063201410.
Relman, A. S. (1989). Economic incentives in clinical investigation. The New England journal of medicine, 320(14), 933-4. https://doi.org/10.1056/NEJM198904063201410
Relman, A S. "Economic incentives in clinical investigation." The New England journal of medicine vol. 320,14 (1989): 933-4. doi: https://doi.org/10.1056/NEJM198904063201410
Relman AS. Economic incentives in clinical investigation. N Engl J Med. 1989 Apr 06;320(14):933-4. doi: 10.1056/NEJM198904063201410. PMID: 2927464.
Copy Download .nbib Format: NLM
TransCelerate makes progress.

Nature reviews. Drug discovery

Mullard A.
PMID: 28356586
Nat Rev Drug Discov. 2017 Mar 30;16(4):229. doi: 10.1038/nrd.2017.63.

No abstract available.

Cite
Mullard A. TransCelerate makes progress. Nat Rev Drug Discov. 2017;16(4):229doi: 10.1038/nrd.2017.63.
Mullard, A. (2017). TransCelerate makes progress. Nature reviews. Drug discovery, 16(4), 229. https://doi.org/10.1038/nrd.2017.63
Mullard, Asher. "TransCelerate makes progress." Nature reviews. Drug discovery vol. 16,4 (2017): 229. doi: https://doi.org/10.1038/nrd.2017.63
Mullard A. TransCelerate makes progress. Nat Rev Drug Discov. 2017 Mar 30;16(4):229. doi: 10.1038/nrd.2017.63. PMID: 28356586.
Copy Download .nbib Format: NLM
National Cancer Institute-supported clinical trials networks.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Abrams J, Kramer B, Doroshow JH, Varmus H.
PMID: 25452448
J Clin Oncol. 2015 Jan 20;33(3):293. doi: 10.1200/JCO.2014.59.5421. Epub 2014 Dec 01.

No abstract available.

Cite
Abrams J, Kramer B, Doroshow JH, et al. National Cancer Institute-supported clinical trials networks. J Clin Oncol. 2014;33(3):293doi: 10.1200/JCO.2014.59.5421.
Abrams, J., Kramer, B., Doroshow, J. H., & Varmus, H. (2015). National Cancer Institute-supported clinical trials networks. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(3), 293. https://doi.org/10.1200/JCO.2014.59.5421
Abrams, Jeffrey, et al. "National Cancer Institute-supported clinical trials networks." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 33,3 (2015): 293. doi: https://doi.org/10.1200/JCO.2014.59.5421
Abrams J, Kramer B, Doroshow JH, Varmus H. National Cancer Institute-supported clinical trials networks. J Clin Oncol. 2015 Jan 20;33(3):293. doi: 10.1200/JCO.2014.59.5421. Epub 2014 Dec 01. PMID: 25452448.
Copy Download .nbib Format: NLM
Level of evidence, sponsorship, conflict of interest policy and commercial impact of PubMed-listed clinical urolithiasis-related trials in 2014.

BJU international

Schoenthaler M, Miernik A, Wilhelm K, Schlager D, Schoeb DS, Adams F, Dahm P, Hein S.
PMID: 26615772
BJU Int. 2016 May;117(5):787-92. doi: 10.1111/bju.13387. Epub 2015 Dec 29.

OBJECTIVES: To evaluate published trials on urolithiasis regarding level of evidence, type of sponsorship and declared conflicts of interest (COIs), and to elucidate a potential commercial impact.MATERIALS AND METHODS: We performed a systematic PubMed(®) literature search using a predefined...

Cite
Schoenthaler M, Miernik A, Wilhelm K, et al. Level of evidence, sponsorship, conflict of interest policy and commercial impact of PubMed-listed clinical urolithiasis-related trials in 2014. BJU Int. 2015;117(5):787-92doi: 10.1111/bju.13387.
Schoenthaler, M., Miernik, A., Wilhelm, K., Schlager, D., Schoeb, D. S., Adams, F., Dahm, P., & Hein, S. (2016). Level of evidence, sponsorship, conflict of interest policy and commercial impact of PubMed-listed clinical urolithiasis-related trials in 2014. BJU international, 117(5), 787-92. https://doi.org/10.1111/bju.13387
Schoenthaler, Martin, et al. "Level of evidence, sponsorship, conflict of interest policy and commercial impact of PubMed-listed clinical urolithiasis-related trials in 2014." BJU international vol. 117,5 (2016): 787-92. doi: https://doi.org/10.1111/bju.13387
Schoenthaler M, Miernik A, Wilhelm K, Schlager D, Schoeb DS, Adams F, Dahm P, Hein S. Level of evidence, sponsorship, conflict of interest policy and commercial impact of PubMed-listed clinical urolithiasis-related trials in 2014. BJU Int. 2016 May;117(5):787-92. doi: 10.1111/bju.13387. Epub 2015 Dec 29. PMID: 26615772.
Copy Download .nbib Format: NLM
How much do clinical trials cost?.

Nature reviews. Drug discovery

Martin L, Hutchens M, Hawkins C, Radnov A.
PMID: 28529317
Nat Rev Drug Discov. 2017 Jun;16(6):381-382. doi: 10.1038/nrd.2017.70. Epub 2017 May 19.

No abstract available.

Cite
Martin L, Hutchens M, Hawkins C, et al. How much do clinical trials cost?. Nat Rev Drug Discov. 2017;16(6):381-382doi: 10.1038/nrd.2017.70.
Martin, L., Hutchens, M., Hawkins, C., & Radnov, A. (2017). How much do clinical trials cost?. Nature reviews. Drug discovery, 16(6), 381-382. https://doi.org/10.1038/nrd.2017.70
Martin, Linda, et al. "How much do clinical trials cost?." Nature reviews. Drug discovery vol. 16,6 (2017): 381-382. doi: https://doi.org/10.1038/nrd.2017.70
Martin L, Hutchens M, Hawkins C, Radnov A. How much do clinical trials cost?. Nat Rev Drug Discov. 2017 Jun;16(6):381-382. doi: 10.1038/nrd.2017.70. Epub 2017 May 19. PMID: 28529317.
Copy Download .nbib Format: NLM
Patient-Funded Trials: Opportunity or Liability?.

Cell stem cell

Wenner DM, Kimmelman J, London AJ.
PMID: 26253199
Cell Stem Cell. 2015 Aug 06;17(2):135-7. doi: 10.1016/j.stem.2015.07.016.

Patient-funded trials (PFTs) are gaining traction as a means of accelerating clinical translation. However, such trials sidestep mechanisms that promote rigor, relevance, efficiency, and fairness. We recommend that funding bodies or research institutions establish mechanisms for merit review of...

Cite
Wenner DM, Kimmelman J, London AJ. Patient-Funded Trials: Opportunity or Liability?. Cell Stem Cell. 2015;17(2):135-7doi: 10.1016/j.stem.2015.07.016.
Wenner, D. M., Kimmelman, J., & London, A. J. (2015). Patient-Funded Trials: Opportunity or Liability?. Cell stem cell, 17(2), 135-7. https://doi.org/10.1016/j.stem.2015.07.016
Wenner, Danielle Marie, et al. "Patient-Funded Trials: Opportunity or Liability?." Cell stem cell vol. 17,2 (2015): 135-7. doi: https://doi.org/10.1016/j.stem.2015.07.016
Wenner DM, Kimmelman J, London AJ. Patient-Funded Trials: Opportunity or Liability?. Cell Stem Cell. 2015 Aug 06;17(2):135-7. doi: 10.1016/j.stem.2015.07.016. PMID: 26253199.
Copy Download .nbib Format: NLM
Creating value with financially adaptive clinical trials.

Nature reviews. Drug discovery

David FS, Bobulsky S, Schulz K, Patel N.
PMID: 26205464
Nat Rev Drug Discov. 2015 Aug;14(8):523-4. doi: 10.1038/nrd4682. Epub 2015 Jul 24.

No abstract available.

Cite
David FS, Bobulsky S, Schulz K, et al. Creating value with financially adaptive clinical trials. Nat Rev Drug Discov. 2015;14(8):523-4doi: 10.1038/nrd4682.
David, F. S., Bobulsky, S., Schulz, K., & Patel, N. (2015). Creating value with financially adaptive clinical trials. Nature reviews. Drug discovery, 14(8), 523-4. https://doi.org/10.1038/nrd4682
David, Frank S, et al. "Creating value with financially adaptive clinical trials." Nature reviews. Drug discovery vol. 14,8 (2015): 523-4. doi: https://doi.org/10.1038/nrd4682
David FS, Bobulsky S, Schulz K, Patel N. Creating value with financially adaptive clinical trials. Nat Rev Drug Discov. 2015 Aug;14(8):523-4. doi: 10.1038/nrd4682. Epub 2015 Jul 24. PMID: 26205464.
Copy Download .nbib Format: NLM
Is academic medicine for sale?.

The New England journal of medicine

Jagger J.
PMID: 10950672
N Engl J Med. 2000 Aug 17;343(7):509; author reply 510.

No abstract available.

Cite
Jagger J. Is academic medicine for sale?. N Engl J Med. 2000;343(7):509; author reply 510
Jagger, J. (2000). Is academic medicine for sale?. The New England journal of medicine, 343(7), 509; author reply 510.
Jagger, J. "Is academic medicine for sale?." The New England journal of medicine vol. 343,7 (2000): 509; author reply 510.
Jagger J. Is academic medicine for sale?. N Engl J Med. 2000 Aug 17;343(7):509; author reply 510. PMID: 10950672.
Copy Download .nbib Format: NLM
Computations for group sequential boundaries using the Lan-DeMets spending function method.

Controlled clinical trials

Reboussin DM, DeMets DL, Kim KM, Lan KK.
PMID: 10822118
Control Clin Trials. 2000 Jun;21(3):190-207. doi: 10.1016/s0197-2456(00)00057-x.

We describe an interactive Fortran program which performs computations related to the design and analysis of group sequential clinical trials using Lan-DeMets spending functions. Many clinical trials include interim analyses of accumulating data and rely on group sequential methods...

Cite
Reboussin DM, DeMets DL, Kim KM, et al. Computations for group sequential boundaries using the Lan-DeMets spending function method. Control Clin Trials. 2000;21(3):190-207doi: 10.1016/s0197-2456(00)00057-x.
Reboussin, D. M., DeMets, D. L., Kim, K. M., & Lan, K. K. (2000). Computations for group sequential boundaries using the Lan-DeMets spending function method. Controlled clinical trials, 21(3), 190-207. https://doi.org/10.1016/s0197-2456(00)00057-x
Reboussin, D M, et al. "Computations for group sequential boundaries using the Lan-DeMets spending function method." Controlled clinical trials vol. 21,3 (2000): 190-207. doi: https://doi.org/10.1016/s0197-2456(00)00057-x
Reboussin DM, DeMets DL, Kim KM, Lan KK. Computations for group sequential boundaries using the Lan-DeMets spending function method. Control Clin Trials. 2000 Jun;21(3):190-207. doi: 10.1016/s0197-2456(00)00057-x. PMID: 10822118.
Copy Download .nbib Format: NLM
[Analysis of costs and results of the economic assessment of health interventions].

Medicina clinica

Prieto L, Sacristán JA, Pinto JL, Badia X, Antoñanzas F, del Llano J.
PMID: 15066252
Med Clin (Barc). 2004 Mar 27;122(11):423-9. doi: 10.1016/s0025-7753(04)74260-8.

No abstract available.

Cite
Prieto L, Sacristán JA, Pinto JL, et al. Análisis de costes y resultados en la evaluación económica de las intervenciones sanitarias. [Analysis of costs and results of the economic assessment of health interventions]. Med Clin (Barc). 2004;122(11):423-9doi: 10.1016/s0025-7753(04)74260-8.
Prieto, L., Sacristán, J. A., Pinto, J. L., Badia, X., Antoñanzas, F., del Llano, J. (2004). Análisis de costes y resultados en la evaluación económica de las intervenciones sanitarias. [Analysis of costs and results of the economic assessment of health interventions]. Medicina clinica, 122(11), 423-9. https://doi.org/10.1016/s0025-7753(04)74260-8
Prieto, Luis, et al. "Análisis de costes y resultados en la evaluación económica de las intervenciones sanitarias." [Analysis of costs and results of the economic assessment of health interventions]. Medicina clinica vol. 122,11 (2004): 423-9. doi: https://doi.org/10.1016/s0025-7753(04)74260-8
Prieto L, Sacristán JA, Pinto JL, Badia X, Antoñanzas F, del Llano J. Análisis de costes y resultados en la evaluación económica de las intervenciones sanitarias. [Analysis of costs and results of the economic assessment of health interventions]. Med Clin (Barc). 2004 Mar 27;122(11):423-9. doi: 10.1016/s0025-7753(04)74260-8. Spanish. PMID: 15066252.
Copy Download .nbib Format: NLM
[Positive drug research].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke

Lund H, Flaten O, Skattebøl A.
PMID: 14714061
Tidsskr Nor Laegeforen. 2003 Sep 25;123(18):2620.

No abstract available.

Cite
Lund H, Flaten O, Skattebøl A. Positivistisk legemiddelforskning. [Positive drug research]. Tidsskr Nor Laegeforen. 2003;123(18):2620
Lund, H., Flaten, O., & Skattebøl, A. (2003). Positivistisk legemiddelforskning. [Positive drug research]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 123(18), 2620.
Lund, Henrik, et al. "Positivistisk legemiddelforskning." [Positive drug research]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke vol. 123,18 (2003): 2620.
Lund H, Flaten O, Skattebøl A. Positivistisk legemiddelforskning. [Positive drug research]. Tidsskr Nor Laegeforen. 2003 Sep 25;123(18):2620. Norwegian. PMID: 14714061.
Copy Download .nbib Format: NLM
European researchers up in arms over new clinical trials edict.

Nature medicine

Bosch X.
PMID: 14595413
Nat Med. 2003 Nov;9(11):1336. doi: 10.1038/nm1103-1336b.

No abstract available.

Cite
Bosch X. European researchers up in arms over new clinical trials edict. Nat Med. 2003;9(11):1336doi: 10.1038/nm1103-1336b.
Bosch, X. (2003). European researchers up in arms over new clinical trials edict. Nature medicine, 9(11), 1336. https://doi.org/10.1038/nm1103-1336b
Bosch, Xavier. "European researchers up in arms over new clinical trials edict." Nature medicine vol. 9,11 (2003): 1336. doi: https://doi.org/10.1038/nm1103-1336b
Bosch X. European researchers up in arms over new clinical trials edict. Nat Med. 2003 Nov;9(11):1336. doi: 10.1038/nm1103-1336b. PMID: 14595413.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 114 entries